HBIO NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Harvard Bioscience Inc · Healthcare · Medical Instruments & Supplies

Open interactive chart View report data
Latest close 6.10 USD
1.7% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 5.6% above the Trend Line and sits at 41.5% of its 52-week range. The latest completed week returned 1.7%, after a -0.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 50/100 conviction, while the latest news-sentiment score is 48/100. Near-term considerations: volume confirmation is below normal; earnings are due in 8d.

Setup score 32 out of 100
Latest Close 6.10 USD 31 Jul 2026
1W Return 1.7% latest completed week
4W Return -0.8% short-term follow-through
12W Return -11.5% quarterly tape
Trend Breadth 36.5% 19 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • The trend backdrop is active with a 3-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 39.41% based on similar historical setup states.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.7% Latest completed week; four-week move -0.8%. Indicator stack 30/52 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 39.41% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bullish 50/100 conviction; expected move 7.9%. News sentiment 48/100 40 relevant articles in the latest sentiment read. Event risk 8d Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 5.6% above the Trend Line and sits at 41.5% of its 52-week range. The latest completed week returned 1.7%, after a -0.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4012-week average 0.30

12-week confirmation

Trend active3/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.40Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -0.8% over four weeks, -11.5% over 12 weeks, and 39.9% over one year. The current trend has remained active for 3 consecutive weeks.

Performance by holding period

1W1.7%
4W-0.8%
12W-11.5%
26W21.8%
52W39.9%
Active trend streak3 weeks
Active weeks in one year19
Trend breadth36.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.25Latest activity-pressure read.
Pressure change-33.0%Four-week change in activity pressure.
Leadership-1.60Latest relative-leadership reading.
RS change60.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength58/100Blend of value, momentum, and quality. Underlying universe rank 43; rank 1 is best.
Value53/100Relative valuation strength. Underlying universe rank 48; rank 1 is best.
Quality52/100Profitability and accounting quality. Underlying universe rank 49; rank 1 is best.
Momentum53/100Medium-term price momentum. Underlying universe rank 48; rank 1 is best.
Growth53/100Revenue and earnings growth. Underlying universe rank 48; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
0.3x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
7.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
57.1%
Gross profit retained from each unit of revenue.
Operating margin
-8.8%
Operating profit retained from revenue.
Free-cash-flow margin
5.5%
Free cash flow generated from revenue.
Return on invested capital
-12.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-6.4%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-23.2%
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.7%
Net share repurchases relative to market value.
Shareholder yield
-0.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-19.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

HBIO shows bullish options pressure with a 49/100 conviction score, put-call volume ratio of 0.17, expected move of 7.9%, and Sharemaestro trend signal active.

Conviction50/100
Expected move7.9%
Put/call volume0.17
Pressure82
Speculation18
Volatility57
Trend agreement21
Open options detail
Insider activity5 / 0

5 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment48/100

Weighted news tone is neutral across 40 relevant articles.

5 positive · 31 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings8dNext report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
Options expected move7.9%Nearest-chain priced movement where available.
52-week drawdown-35.1%Distance below the 52-week high.
13-week volatility7.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+42.2%Week of 17 Apr.
Worst week-23.9%Week of 15 May.
Latest week+1.7%Week of 31 Jul.

Shape of recent returns

Strong gains11
Modest gains4
Flat weeks0
Modest losses5
Sharp losses6
Recent vol7.8%13-week weekly-return volatility.
Base vol11.2%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew8.9% / -7.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape33/100

Trend, activity pressure, participation, and risk combine to a 33/100 tape read.

 Indicator analysis43/100

Latest 12-week confirmation: trend 3/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.40; No reversal markers Next-Week ExpectancyNegative 39.41%

Next-week expectancy is negative with a 39.41% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors53/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Tiny Titans rank 22; Buyback Yield rank 76 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options52/100

HBIO shows bullish options pressure with a 49/100 conviction score, put-call volume ratio of 0.17, expected move of 7.9%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 7.9% Sentiment48/100

Weighted news tone is neutral across 40 relevant articles.

Harvard Bioscience Inc (HBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk Insiders5 / 0

5 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings8d

Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20266.10 USD1.7%5.77 USD20.42 USD0.25-1.6050.5KOn
24 Jul 20266.00 USD-3.7%5.79 USD20.69 USD0.40-2.4863.6KOn
17 Jul 20266.23 USD1.5%5.82 USD20.96 USD0.49-0.6261.3KOn
10 Jul 20266.14 USD-0.2%5.87 USD21.25 USD0.38-5.9565.4KOff
3 Jul 20266.15 USD1.8%5.91 USD21.56 USD0.38-4.0064.7KOff
26 Jun 20266.04 USD2.9%5.96 USD21.89 USD0.36-4.8259.9KOff
19 Jun 20265.87 USD-3.5%6.01 USD22.20 USD0.32-11.65106.5KOff
12 Jun 20266.08 USD-1.9%6.02 USD22.54 USD0.26-6.48104.8KOff
5 Jun 20266.20 USD5.4%6.04 USD22.85 USD0.20-2.77156.3KOff
29 May 20265.88 USD5.2%6.02 USD23.16 USD0.33-11.68104.9KOff
22 May 20265.59 USD6.5%5.99 USD23.49 USD0.45-13.80152.6KOff
15 May 20265.25 USD-23.9%5.94 USD23.83 USD0.61-17.86166.9KOff
8 May 20266.89 USD8.4%5.89 USD24.17 USD0.667.73216.3KOff
1 May 20266.36 USD-7.3%5.80 USD24.48 USD0.185.57105.0KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.